论文部分内容阅读
目的 了解利培酮治疗儿童期首发精神分裂症患者的疗效和安全性。方法 对 70例年龄 <1 4岁首次发病患儿用利培酮治疗 6周 ,以阳性和阴性症状量表 ( PANSS)和简明精神病评定量表 ( BPRS)评定临床疗效。以副反应量表 ( TESS)和实验室监测评价安全性 ,于基线时 ,实验第 1、2、4、6周末分别评定各量表。统计方法为描述性分析和配对 t检验。结果 共收集有效病例 70例 ,其中基本痊愈 3 4.3 % ( 2 4/ 70 ) ,显著进步 45 .7% ( 3 2 / 70 ) ,好转 1 0 % ( 7/ 70 )和无效 1 0 % ( 7/ 70 )。 BPRS总分、PANSS总分、PANSS各分量表分治疗前后比较均有显著性差异 ( P<0 .0 1 ) ,利培酮对阳性、阴性症状以及一般精神病性症状均有良好疗效。副反应主要为锥体外系反应。结论 对儿童期首发精神分裂症 ,利培酮疗效较好 ,安全性高
Objective To investigate the efficacy and safety of risperidone in the treatment of first episode schizophrenia in childhood. Methods Seventy patients aged <14 years old with risperidone were treated with risperidone for 6 weeks. The positive and negative symptom scales (PANSS) and Simple Mental Illness Rating Scale (BPRS) were used to assess the clinical efficacy. Safety was assessed by TESS and laboratory monitoring. At baseline, the scales were assessed at the end of the first, second, fourth and sixth week of the experiment. Statistical methods were descriptive analysis and paired t-test. Results A total of 70 effective cases were collected, of which 43.3% (24/70) were basically cured, 45.7% (32/70), 10% (7/70), and 10% / 70). BPRS total score, PANSS total score, PANSS subscales were significantly different before and after treatment (P <0 01), risperidone positive, negative symptoms and general psychiatric symptoms have a good effect. Side effects are mainly extrapyramidal reactions. Conclusion Schizophrenia in childhood, risperidone better efficacy, high safety